GlassScriptPhysician profile
Syed A Rizvi
NPI 1659395754
$1,487.27
in general payments reported to CMS, 2019-2025
20 companies · $68.50 in 2025
The $68.50 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $41.86 · 2021: $95.11 · 2022: $484 · 2023: $155 · 2024: $405 · 2025: $68.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $326.88 | 2019-2024 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $163.10 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $124.22 | 2022-2023 | Benlysta |
| Vifor Pharma, INC. | $122.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.33 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.67 | 2019 | |
| Calliditas Therapeutics US INC. | $67.52 | 2022-2024 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $62.54 | 2019-2024 | Jynarque |
| Organogenesis INC. | $55.38 | 2023 | Puraply |
| Novo Nordisk INC | $43.61 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $38.42 | 2022-2024 | Crysvita |
| Fresenius USA Marketing, INC. | $36.85 | 2021-2024 | Velphoro |
| Travere Therapeutics, INC. | $31.49 | 2025 | |
| Mallinckrodt Hospital Products INC. | $27.84 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $20.15 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $18.90 | 2025 | Rayaldee |
| Boston Scientific Corporation | $18.31 | 2024 | Wavewriter Alpha Prime 16 |
| Akebia Therapeutics INC | $18.11 | 2025 | Vafseo |
| Csl Behring | $17.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.